A few weeks ago, a patient called me, questioning whether IMIQUIMOD was associated with vomiting. The patient had been applying IMIQUIMOD once a week to their facial skin for maintenance therapy of ACTINIC KERATOSES. At first, I thought, “How could this be? How could a topical medication make someone nauseous and vomit?” After researching this question, I found out that it is true: approximately 1% of patients in clinical trials develop vomiting. This, I suppose, is from the generation of interferon.